Announcement PDF Emyria ASX Announcement | 29 September 2026 1 ASX RELEASE. 29 September 2026 EMYRIA OPENS SYDNEY EMPAX CLINIC WITH FIRST PATIENTS HAVING COMMENCED TREATMENT Sydney opening establishes a four-state national clinical footprint, with treatment infrastructure, specialist workforce and first patients in treatment. Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based intensive mental-health care, is pleased to announce that its first New South Wales- based Empax clinic is now operational, with treatment having commenced for the clinic's first patients. The milestone represents Emyria's expansion into a fourth Australian state, with existing clinics operational across Western Australia, Queensland, and Victoria. The activation builds on the Company's mission to establish a nationally-scaled Empax clinic network capable of delivering evidence-based mental health treatments for patients with post-traumatic stress disorder (PTSD) and treatment-resistant depression. The new Empax clinic is located within Matilda Nepean Private Hospital in Kingswood, Western Sydney, and comprises four treatment beds designed to support the delivery of psychiatrist-led treatment programs within a hospital-integrated setting1 . • EXPANSION MILESTONE ACHIEVED1 - Clinic successfully opened on schedule and supports Emyria’s strategy to build a nationally scaled network of specialist Empax clinics. • NATIONAL CLINICAL FOOTPRINT – Sydney clinic establishes Emyria’s presence across Australia’s four most populous states – New South Wales, Victoria, Queensland, and Western Australia – strengthening the Company’s national treatment-delivery platform. • SYDNEY CLINIC INCREASES TREATMENT CAPACITY – National treatment bed capacity increases from 14 to 18 allowing for up to 90 dosing sessions per week. • FIRST PATIENTS COMMENCED TREATMENT – Commencement of therapeutic treatment at the centre has officially begun, with further treatments to be delivered over the coming weeks. • REAL-WORLD EVIDENCE CAPACITY – Sydney will increase Emyria’s capacity to generate real-world clinical evidence from patients treated within regulated healthcare settings, strengthening the evidence generated through its Australian delivery platform. • AUSTRALIAN PLATFORM SUPPORTING U.S. STRATEGY – Emyria continues to assess opportunities to apply its Australian treatment delivery experience and evidence generation capabilities in the United States, following its recent selection to present at the U.S. FDA’s psychedelic medicines hearing2 and the appointment of former U.S. Secretary of Veterans Affairs Dr. David Shulkin as strategic advisor3 . ASX RELEASE. Emyria ASX Announcement | 29 September 2026 2 First patients have been approved for treatment under the New South Wales workers’ compensation scheme, providing evidence of growing reimbursement pathways whilst supporting Emyria’s objective of integrating evidence based mental-health therapies into established healthcare and payer-supported settings. NATIONAL CLINICAL PRESENCE The Sydney opening establishes Emyria’s clinical presence across Australia’s four most populous states and further develops a national platform spanning patient access, workforce development, treatment delivery and real-world evidence generation. The clinic adds four treatment beds to Emyria’s network taking the total from 14 to 18, and has commenced operations with trained clinicians and Authorised Prescribers already in place. This platform addresses a substantial healthcare need. Mental Health and substance use disorders accounted for 15% of Australia’s total disease burden in 20244 , while the latest ABS National Study of Mental Health and Wellbeing found approximately 4.3 million Australians aged 16–85 experienced a mental disorder within a 12-month period5 . AUSTRALIAN EXPERIENCE SUPPORTING U.S. STRATEGY Emyria’s Australian platform is providing practical experience in clinical governance, therapist training, patient screening, treatment delivery, payer-supported access and real-world evidence generation. This operating experience provides practical insights into the clinical infrastructure required to integrate these therapies into regulated healthcare systems beyond traditional clinical trials. The Company continues to assess strategic opportunities to apply this experience in the United States following its recent selection to present at the U.S. Food and Drug Administration’s public hearing on the potential future therapeutic use of psychedelic drugs2 , and the appointment of former U.S. Secretary of Veterans Affairs Dr David Shulkin as Strategic Advisor3 . Emyria Executive Chair Greg Hutchinson commented: “The opening of our Sydney clinic establishes Emyria across Australia’s four most populous states and adds further specialist clinical infrastructure to support the delivery of these treatments at scale. “With trained clinicians, Authorised Prescribers, treatment capacity and approved patients now in place, our focus is on converting this platform into improved patient outcomes, increased treatment volumes and high-quality real-world evidence.” References: 1. See ASX announcement 29th April 2026 2. See ASX announcement 16th September 2026 3. See ASX announcement 21st September 2026 4. https://www.aihw.gov.au/mental-health/topic-areas/health-wellbeing/burden-of-disease 5. https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and- wellbeing/latest-release This announcement has been approved by the Board of Emyria. ASX RELEASE. Emyria ASX Announcement | 29 September 2026 3 For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 29 September 2026 4 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs